Stay Alert for New GLP-1 Agonists and Flozins During Transitions of Care

Patients will report taking new diabetes meds during admission histories as more GLP-1 agonists and SGLT2 inhibitors hit the market.

GLP-1 agonists are becoming a crowded group. Once-WEEKLY exenatide (Bydureon BCise) and semaglutide (Ozempic) bring the tally to eight.

Bydureon BCise is extended-release exenatide, like Bydureon. You may hear it gives more consistent drug levels in a simpler pen device.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals